, many biochemical parameters, for instance, liver enzymes, platelets, albumin, and scoring systems based on aforementioned markers, have been used to investigate NAFLD ( 14 , 15 , 16 ).
Pentoxifylline (PTX), a phosphodiesterase inhibitor, although commonly used for peripheral vascular disease, is one of the antioxidants considered for NASH treatment. Besides its antioxidant activity and inhibition of proinflammatory cytokine production (tumor necrosis factor alpha – TNF-α), it exerts pleiotropic pharmacological effects ( 17 ). Additionally, it has been implied
Roland Kaufmann, Franziska Mußbach, Annett Urbanek, Utz Settmacher and Ferdinand von Eggeling
17. Gluck N, Schwob O, Krimsky M, Yedgar S. Activation of cytosolic phospholipase A2 and fatty acid transacylase is essential but not sufficient for thrombin-induced smooth muscle cell proliferation. Am J Physiol Cell Physiol 2008; 294: C1597-603.
18. Leslie CC. Properties and regulation of cytosolic phospholipase A2. J Biol Chem 1997; 272: 16709-12.
19. Cardoso CC, Paviani ER, Cruz LA, Guma FC, Borojevic R, Guaragna RM. Effect of pentoxifylline on arachidonic acid metabolism, neutral lipid synthesis and accumulation during induction of the lipocyte phenotype